# Codex Review: medical_monitoring_patient_journey_research_20260809

Date: 2026-08-09
Codex direct output: `reviews/medical_monitoring_patient_journey_research_20260809.md`

## Verdict

Pass for the refreshed research/design contract. The isolated R1 Patient Journey slice has since
passed its own browser acceptance; this review now governs the R3-R5 expansion and still does not
accept R1 overall or authorize real-project execution.

## Hermes / Route Disposition

Hermes execution or conference was not dispatched for this bounded refresh. Codex retained direct
source verification and final authority. The already-completed Slice 4 used its own tracked execution
and browser acceptance gate; future R3-R5 implementation remains separately gated.

## Boundary Check

- Read-only external research and local artifact inspection stayed inside the medical-monitoring workbench and public sources.
- Writes are limited to the Patient Journey research record, its tracked task records, System Design v1.1, and implementation plan v1.1.
- No medical-writing, product, service, shared runtime, accepted Slice 3/4 implementation file, or real-project file was changed.

## Codex Verification

- Official repositories/papers were refreshed for clinDataReview/patientProfilesVis, TrialView,
  OHDSI ATLAS/Pathways, Medication Timeline, Health Timeline, LabVis, Tendril Plot, vis-timeline,
  Apache ECharts and Section 508/WCAG color guidance.
- vis-timeline is Apache-2.0 OR MIT; Apache ECharts and OHDSI ATLAS are Apache-2.0. They remain
  candidates only; no dependency was installed or adopted before a scale/accessibility benchmark.
- Current Slice 4 browser evidence confirms a shared visit axis, synchronized views, source jump and
  separate AE/MH/CM/IP/examination/hospitalization/symptom event/risk encoding.
- `subject-timeline-builder`, `clinical-patient-profile-html`, and `ae-risk-assessment` contracts were applied to visit/date/source/risk semantics.
- The refreshed contract corrects the audience language: eight clinical tracks, domain-specific risk
  labels and a hard ban on “正式事实”“候选信号”“只读xx” and backend identity terms.

## Delegated-Agent Output Review

The report separates externally observed capabilities, local observation, inference, and adoption decision. Proprietary EventFlow and unverified TrialView implementation are explicitly reference-only. No external package was adopted solely because of a permissive license.

## Residual Risk

Dense-event performance, eight-domain adaptation and heterogeneous-study behavior remain unmeasured.
R3-R5 must add PD/eligibility/prohibited-medication and efficacy/PRO/PK lanes without project
hard-coding, then benchmark hundreds-to-thousands of events before selecting a visualization engine.
